Compare ALEMBIC LTD with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs AJANTA PHARMA - Comparison Results

ALEMBIC LTD     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD AJANTA PHARMA ALEMBIC LTD/
AJANTA PHARMA
 
P/E (TTM) x 73.7 23.5 313.6% View Chart
P/BV x 2.6 4.1 63.2% View Chart
Dividend Yield % 0.4 0.9 45.8%  

Financials

 ALEMBIC LTD   AJANTA PHARMA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
AJANTA PHARMA
Mar-19
ALEMBIC LTD/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs721,422 5.1%   
Low Rs34898 3.8%   
Sales per share (Unadj.) Rs4.7233.5 2.0%  
Earnings per share (Unadj.) Rs6.144.0 13.9%  
Cash flow per share (Unadj.) Rs6.252.2 12.0%  
Dividends per share (Unadj.) Rs0.209.00 2.2%  
Dividend yield (eoy) %0.40.8 48.7%  
Book value per share (Unadj.) Rs40.7255.1 15.9%  
Shares outstanding (eoy) m267.0388.02 303.4%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x11.35.0 226.8%   
Avg P/E ratio x8.726.4 32.9%  
P/CF ratio (eoy) x8.522.2 38.1%  
Price / Book Value ratio x1.34.5 28.6%  
Dividend payout %3.320.5 16.0%   
Avg Mkt Cap Rs m14,139102,081 13.9%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m2074,307 4.8%   
Avg. sales/employee Rs ThNM3,022.6-  
Avg. wages/employee Rs ThNM633.4-  
Avg. net profit/employee Rs ThNM569.1-  
INCOME DATA
Net Sales Rs m1,25520,554 6.1%  
Other income Rs m370211 175.6%   
Total revenues Rs m1,62520,765 7.8%   
Gross profit Rs m1115,664 2.0%  
Depreciation Rs m38721 5.2%   
Interest Rs m212 14.7%   
Profit before tax Rs m4425,143 8.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m241,273 1.9%   
Profit after tax Rs m1,6303,870 42.1%  
Gross profit margin %8.927.6 32.1%  
Effective tax rate %5.424.8 21.9%   
Net profit margin %129.818.8 689.7%  
BALANCE SHEET DATA
Current assets Rs m1,86711,812 15.8%   
Current liabilities Rs m5913,776 15.7%   
Net working cap to sales %101.639.1 260.0%  
Current ratio x3.23.1 101.0%  
Inventory Days Days9477 121.8%  
Debtors Days Days7482 90.1%  
Net fixed assets Rs m1,79114,398 12.4%   
Share capital Rs m534175 304.5%   
"Free" reserves Rs m10,32422,277 46.3%   
Net worth Rs m10,85822,452 48.4%   
Long term debt Rs m417 624.2%   
Total assets Rs m11,59126,962 43.0%  
Interest coverage x260.9444.3 58.7%   
Debt to equity ratio x00 1,290.8%  
Sales to assets ratio x0.10.8 14.2%   
Return on assets %14.114.4 97.8%  
Return on equity %15.017.2 87.1%  
Return on capital %15.223.0 66.2%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1910,682 0.2%   
Fx outflow Rs m2642,102 12.6%   
Net fx Rs m-2448,580 -2.8%   
CASH FLOW
From Operations Rs m2363,748 6.3%  
From Investments Rs m-224-2,228 10.1%  
From Financial Activity Rs m-27-1,475 1.8%  
Net Cashflow Rs m-1545 -32.7%  

Share Holding

Indian Promoters % 64.0 73.8 86.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 1.6 12.9%  
FIIs % 9.7 7.6 127.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 17.0 153.5%  
Shareholders   54,701 20,968 260.9%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   PROCTER & GAMBLE HEALTH  CIPLA  TORRENT PHARMA  SUVEN LIFESCIENCES  STERLING BIOTECH  

Compare ALEMBIC LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Sep 20, 2019 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - WOCKHARDT COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS